27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The plush toy used in this study offered marginally greater value for money than PARO in improving agitation. 4 key findings →
Design: randomized controlled trial Participants: 415 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Due to valued informal care, costs of care for community-living patients with moderate dementia are significantly higher than for patients with mild dementia. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Dual-eligible older persons are at greater risk for decline in function and cognition after an ICU hospitalization than their more advantaged counterparts. 2 key findings →
Design: cohort study Participants: 641 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Preventable hospital readmissions have been recognized as indicators of hospital quality, a source of increased healthcare expenditures, and a burden for patients, families, and caregivers. 2 key findings →
Design: cohort study Participants: 5,133 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Program participants (n = 382 men, n = 701 women; mean [SD] age, 82.10 [7.90] years; age range 54-101 years) were less likely to be admitted to a long-term care facility (hazard ratio, 0.60; 95% CI, 0.59-0.61) than those not participating in the dementia care program (n = 759 men, n = 1407 women; mean [SD] age, 82.42 [8.50] years; age range, 34-103 years). 1 key finding →
Design: case-control study Participants: 382 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Underclassification of dementia from claims records can be partially remedied by increasing the period during which claims are compiled, but additional diagnostic sources will likely be needed to increase prevalence counts closer to 100% of true cases. 2 key findings →
Design: prospective cohort Participants: 4,166 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Hospitalised people with cognitive impairment experience significantly greater length of stay and when discharged to their usual residence are more likely to be readmitted to hospital within 28 days compared with those without cognitive impairment. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
GIM services care for a markedly heterogeneous population but the most common conditions were similar across 7 hospitals. 3 key findings →
Design: cross-sectional Participants: 223 Evidence: low
Full summary, score breakdown and related studies → Original source
The average total cost to Medicare of persons with a claims-based diagnosis of AD was $6021 versus $2310 (P < .001) for persons without a diagnosis. 2 key findings →
Design: cross-sectional Participants: 10,858 Evidence: low
Full summary, score breakdown and related studies → Original source
Different information sources yield widely varied prevalence and expenditure estimates. 1 key finding →
Participants: 57,669 Evidence: low
Full summary, score breakdown and related studies → Original source
Most people with dementia prefer to remain in their own homes, and funding bodies see this as cheaper than institutionalisation. 1 key finding →
Participants: 3,075 Evidence: low
Full summary, score breakdown and related studies → Original source
Delayed discharge is associated with higher hospital costs and complication rates especially nosocomial infections. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Medicare beneficiaries with ADRD were at a higher risk of PAHs for certain uncontrolled comorbidities and incurred higher Medicare expenditures compared with matched controls without dementia. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Having an exam reflects multiple factors. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The prevalence of low vision in the Medicare population was 994/100,000 and increased significantly with age, Black (1,854/100,000) or Hispanic (2,862/100,000) race/ethnicity, female gender (1,181/100,000), and Medicaid eligibility (2,975/100,000). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Utilization and costs for patients with AD were higher compared to controls and were substantially higher for patients with both AD and co-morbid diseases commonly targeted for disease management. 5 key findings →
Participants: 1,366 Evidence: low
Full summary, score breakdown and related studies → Original source
The burden of dementia in Korea is expected to considerably increase alongside the elderly population in the future. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Earlier treatment leads to a small delay in institutionalization among AD patients, resulting in significant costs savings to Medicaid. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Database linkage to Medicare claims records is an efficient and reasonably accurate tool to identify dementia cases in a population-based cohort. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings may suggest potential deficiencies in ambulatory care and postdischarge care related to managing comorbidities among Medicare fee-for-service ADRD patients. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cost estimates did not differ significantly between CN and MCI. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia poses a substantial additional burden to the German social security system, with the long-term care sector being more seriously challenged than the health care sector. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Artificial intelligence (AI) is rapidly expanding into dementia-related health and social care, with proposed applications ranging from early risk detection and monitoring to care coordination and service planning. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia poses an on-going Canadian challenge due to an aging population, with cases projected to rise significantly by 2050. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →